Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer
暂无分享,去创建一个
Chikuma Hamada | Kazuhiro Nishikawa | Naotoshi Sugimoto | Hiroshi Imamura | Akihito Tsuji | Satoshi Tanabe | Tomohiro Nishina | Hirofumi Fujii | Hirofumi Yasui | Yasuhide Yamada | H. Imamura | N. Sugimoto | I. Hyodo | S. Tanabe | H. Miwa | Y. Niwa | H. Fujii | M. Gotoh | C. Hamada | K. Amagai | T. Nishina | Masahiro Gotoh | K. Yamaguchi | S. Hironaka | H. Yasui | A. Tsuji | Ichinosuke Hyodo | Shuichi Hironaka | Ken Shimada | Hideaki Bando | Kenji Amagai | Keisho Chin | Yasumasa Niwa | Masahiro Tsuda | Kensei Yamaguchi | Hisateru Yasui | Hiroto Miwa | M. Tsuda | K. Nishikawa | H. Yasui | H. Bando | K. Shimada | K. Chin | Y. Yamada
[1] K Nishikawa,et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] Jacques Ferlay,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] , 2013 .
[3] H. Wildiers,et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Hiroshi Nishimoto,et al. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2012, Japanese journal of clinical oncology.
[5] C. Bokemeyer,et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[7] Murielle Mauer,et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Ken Kato,et al. Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer , 2013, Journal of Cancer Research and Clinical Oncology.
[9] L. Rubenstein,et al. Impacts of Geriatric Evaluation and Management Programs on Defined Outcomes: Overview of the Evidence , 1991, Journal of the American Geriatrics Society.
[10] N. Boku,et al. Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer , 2013, International Journal of Clinical Oncology.
[11] H. Cohen,et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). , 2005, Critical reviews in oncology/hematology.
[12] Masahiro Takeuchi,et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. , 2008, The Lancet. Oncology.